Alnylam Pharmaceuticals Inc. is experiencing a positive turn in its stock performance amidst recent challenges.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is rising today, with shares up by 2.55% to close at CA$230.25. This uptick comes as the company navigates a challenging market environment, marked by recent declines in its stock price over the past few months.
Investor takeaway: Investors may view this rise as a potential rebound opportunity, especially given Alnylam's strong fundamentals and the ongoing developments in its RNAi pipeline.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$30.03B
P/E
37.8x
52W high
$495.55
52W low
$197.81
1W change
-2.88%
Beta
0.27
Analyst Price Targets
Based on 29 analysts covering ALNY · as of Oct 5, 2026
Wall Street analysts forecast ALNY stock price to rise 65.3% over the next 12 months.
Consensus
Buy4.31 / 5.00
Avg. Target
C$371.12
+65.3% Upside
Current Price
C$224.53
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
45.9%
Annualized
90-Day Vol
70.8%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$187.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$211.56 | C$180.59 – C$247.82 |
| 60 trading days | C$199.33 | C$159.36 – C$249.32 |
| 90 trading days | C$187.81 | C$142.79 – C$247.03 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
2.55% Increase in Stock Price
The recent increase in Alnylam's stock price reflects a possible shift in investor sentiment after a period of significant declines.
Bull case
Alnylam's RNA interference (RNAi) technology has significant potential, with a strong pipeline of over 25 programs that could lead to new approvals and revenue streams. The recent focus on undervaluation might attract investors looking for growth in the biotech sector.
Bear case
Despite today's rise, Alnylam's stock has struggled recently, with a 43.5% decline year-to-date. Investors should be cautious of potential risks related to clinical trial outcomes and market sentiment that could further impact stock performance.
Market Context
Advertisement
Alnylam's stock has faced a tough few months, dropping 43.5% year-to-date. However, today's 2.55% increase may indicate a shift in market sentiment as investors reassess the company's potential. The biotech sector has been volatile, and Alnylam's recent performance reflects broader industry challenges.
Fundamental Strength
Despite recent declines, Alnylam boasts strong fundamentals with a market cap of approximately $30 billion and a P/E ratio of 37.86. The company’s RNAi pipeline, which includes over 25 programs, presents numerous opportunities for growth and could justify its current valuation, as analysts suggest it may be undervalued compared to its fair value.
Looking Ahead
Investors are keenly watching Alnylam's upcoming clinical trials and product launches. Positive results could further boost investor confidence and drive the stock price higher. However, the company must navigate potential risks associated with its pipeline to maintain momentum.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
